Research Triangle Park, North Carolina, United States:
Quintiles Founder Dennis Gillings, CBE, has received the SCRIP Lifetime
Achievement Award and the company he started has been named “CRO of the
Year” at the 2012 SCRIP Awards in London.
Quintiles Founder and Executive Chairman Dennis Gillings, CBE. (Photo: Business Wire)
The SCRIP Awards acknowledge excellence in the biopharmaceutical
industry, based on judging by an independent panel of 16 life sciences experts.
The 8th annual awards ceremony, held on November 28th at The
Lancaster hotel in London, was attended by more than 500 industry
leaders from around the world.
Being named CRO of the Year by SCRIP is a prestigious honor for
Quintiles, the world’s leading provider of biopharmaceutical services.
It is one of the most competitive awards bestowed by SCRIP, and
Quintiles has received it three times in the past four years.
Likewise, Dennis Gillings’ lifetime achievement award is equally
celebrated. Mike Ward Chief Content Officer for Datamonitor Healthcare
and Scrip Intelligence said, “Scrip’s Lifetime Achievement Award is
reserved for an individual who has made an outstanding contribution to
the pharmaceutical/biotech industry. In founding Quintiles, Dennis
Gillings made an indelible impact on drug development by pioneering the
Clinical Research Organization industry, revolutionizing the field to
the extent that clinical trials expertise now rests with these
companies. The CRO sector is still fast growing and plays a crucial role
in drug development.”
“I am honored to receive this award,” said Dr. Gillings. “It is humbling
to be recognized by this prestigious panel, and I share this with
Quintiles’ employees, past and present, around the world who make our
company what it is today. During these past three decades, many diseases
have gone from being life threatening to manageable thanks to the work
we have done with our biopharmaceutical customers.
“As we look ahead, I believe we on are on the cusp of many new
discoveries which will further transform healthcare. It is my goal to
ensure that Quintiles can help enable that innovation to make a
difference to patients around the world.”
Dr. Gillings has invested his 40-plus year career working to improve
health around the world, beginning in 1971 as a professor of
biostatistics at the University of North Carolina. In April 2012, he
stepped away from the day-to-day operations of Quintiles and he
continues to serve as executive chairman. Today, Quintiles is the
largest global provider of services to the pharmaceutical and
Under Dr. Gillings’ leadership, Quintiles helped develop or
commercialize all of 2011’s top 50 best-selling products or compounds,
top 30 best-selling cardiovascular products or compounds, and top 40
best-selling oncology products or compounds.
Other recent awards for excellence received by Quintiles include:
Ranked in top 25 in the World’s
Best Multinational Workplaces
list from the Great Place to Work
Institute in 2011 and 2012.
Placed sixth in the InformationWeek
500 technology innovators
rankings for Quintiles' collaboration
with Eli Lilly on an IT-enabled project to eliminate inefficiencies
and use "big data" to drive better drug development decisions.
Recognized by the Great Place to Work Institute in 2012Πas one of the
top workplaces in Canada, Germany, Ireland, Italy, Mexico, Scotland,
Spain, United Kingdom and Europe.
Named Best CRO in the Vaccine
Industry Excellence (ViE) Awards
Named to Computerworld magazine’s 100
Best Places to Work in IT
list for a third time.
Quintiles is the world’s leading provider of biopharmaceutical services.
With a network of more than 27,000 professionals working in more than 80
countries, we have helped develop or commercialize all of the top 50
best selling drugs on the market. With extensive therapeutic, scientific
and analytics expertise, we help biopharmaceutical and health sciences
customers navigate the increasingly complex landscape with more
predictability to enable better outcomes.
to subscribe to Mobile Alerts for Quintiles.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20121128006448/en/
MULTIMEDIA AVAILABLE : http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50491902&lang=en
Phil Bridges, + 1-919-998-1653 (office)
Greg Connors, +1-919-998-2000